530616 Sigma-AldrichACE2 Inhibitor, MLN-4760 - CAS 305335-31-3 - Calbiochem
A cell-permeable, highly potent inhibitor of angiotensin converting enzyme 2 (ACE2; IC₅₀ = 440 pM).
More>> A cell-permeable, highly potent inhibitor of angiotensin converting enzyme 2 (ACE2; IC₅₀ = 440 pM). Less<<Synonymes: (S,S)-2-(1-Carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)-ethylamino)-4-methylpentanoic acid, 2(S)-(1(S)-Carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)-ethylamino)-4-methylpentanoic acid, Angiotensin-Converting Enzyme-Related Carboxypeptidase Inhibitor, ML00106791, GL-1001, GL1001, MLN4760
Produits recommandés
Aperçu
Replacement Information |
---|
Tableau de caractéristiques principal
CAS # | Empirical Formula |
---|---|
305335-31-3 | C₁₉H₂₃Cl₂N₃O₄ |
Prix & Disponibilité
Référence | Disponibilité | Conditionnement | Qté | Prix | Quantité | |
---|---|---|---|---|---|---|
5.30616.0001 |
|
Flacon en verre | 2 mg |
|
— |
Product Information | |
---|---|
CAS number | 305335-31-3 |
Form | White powder |
Hill Formula | C₁₉H₂₃Cl₂N₃O₄ |
Chemical formula | C₁₉H₂₃Cl₂N₃O₄ |
Reversible | Y |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | soluble human ACE2 |
Primary Target IC<sub>50</sub> | 440 pM for soluble human ACE2 |
Purity | ≥97% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Référence | GTIN |
5.30616.0001 | 04055977260960 |
Documentation
ACE2 Inhibitor, MLN-4760 - CAS 305335-31-3 - Calbiochem FDS
Titre |
---|
ACE2 Inhibitor, MLN-4760 - CAS 305335-31-3 - Calbiochem Certificats d'analyse
Titre | Numéro de lot |
---|---|
530616 |
Références bibliographiques
Aperçu de la référence bibliographique |
---|
Tikellis, C., et al. 2014. Am. J. Physiol. Renal Physiol. 306, F773. Grobe, N., et al. 2013. Am. J. Physiol. Cell Physiol 304, C945. Ye, M., et al. 2012. Hypertension 60, 730. Dilauro, M., et al. 2010. Am. J. Physiol. Renal Physiol. 298, F1523. Thomas, M.C., et al. 2010. Circ. Res. 107, 888. Trask, A.J., et al. 2010. Am. J. Hypertens. 23, 687. Byrnes, J.J., et al. 2009. Inflamm. Res. 58, 819. Soler, M.J., et al. 2007. Kidney Int. 72, 614. Towler, P., et al. 2004. J. Biol. Chem. 279, 17996. Dales, N.A., et al. 2002. J. Am. Chem. Soc. 124, 11852. |